0001209191-23-041393.txt : 20230705 0001209191-23-041393.hdr.sgml : 20230705 20230705210845 ACCESSION NUMBER: 0001209191-23-041393 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230703 FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230705 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gauthier George CENTRAL INDEX KEY: 0001857434 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39045 FILM NUMBER: 231071793 MAIL ADDRESS: STREET 1: C/O IGM BIOSCIENCES, INC. STREET 2: 325 E. MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IGM Biosciences, Inc. CENTRAL INDEX KEY: 0001496323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770349194 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 325 E MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-965-7873 MAIL ADDRESS: STREET 1: 325 E MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 FORMER COMPANY: FORMER CONFORMED NAME: Palingen, Inc. DATE OF NAME CHANGE: 20100712 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-07-03 0 0001496323 IGM Biosciences, Inc. IGMS 0001857434 Gauthier George C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 0 1 0 0 Chief Commercial Officer 0 Common Stock 2023-07-03 4 S 0 936 9.4209 D 40017 D The sale reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan, entered into on December 29, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). This transaction was executed in multiple trades at prices ranging from $9.22 to $9.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. /s/ Misbah Tahir, by power of attorney 2023-07-05